Lithium (Low-Dose): Benefits, Forms, Dosing, and Side Effects

Lithium is a naturally occurring alkali metal and trace mineral found in varying concentrations in soil, water, and certain foods. While not classified as an "essential" mineral (i.e., no established biological requirement has been proven), lithium has a long history in medicine and an emerging body of evidence suggesting potential benefits at very low doses for mood, cognition, and neuroprotection [1][2].

At high doses, lithium is a well-established prescription medication for bipolar disorder (manic-depressive illness). Therapeutic doses for bipolar disorder typically range from 900 to 1,800 mg of lithium carbonate per day — of which approximately 18.8% is elemental lithium, yielding 169 to 338 mg of elemental lithium daily. At these pharmacological doses, blood lithium levels must be closely monitored (therapeutic range 0.6–1.2 mEq/L) because of a narrow therapeutic index and significant risks of kidney damage, thyroid dysfunction, and toxicity [3][4].

In contrast, a growing area of interest concerns very low-dose lithium — typically 0.3 to 20 mg of elemental lithium per day — available over the counter as dietary supplements, most commonly in the form of lithium orotate or lithium aspartate [1][2]. These doses are orders of magnitude below those used for bipolar disorder and do not produce measurable serum lithium levels in the therapeutic range.

Table of Contents

• Overview
• Forms and Bioavailability
• Evidence for Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• References

Overview

The rationale for low-dose lithium supplementation stems from several converging lines of evidence: epidemiological studies linking trace lithium exposure in drinking water to lower rates of suicide, dementia, and violent crime; small clinical trials suggesting cognitive stabilization in Alzheimer's disease; and preclinical research demonstrating neuroprotective, anti-inflammatory, and anti-aging mechanisms at very low concentrations [1][2][5][6].

Lithium exerts its biological effects through several well-characterized molecular pathways. The primary mechanism involves inhibition of glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase that regulates multiple cellular processes including glycogen metabolism, cell proliferation, apoptosis, and neuronal signaling [2][7]. By competitively displacing magnesium at the catalytic site of GSK-3, lithium inhibits the enzyme's activity, with downstream effects including reduced hyperphosphorylation of tau protein (a hallmark of Alzheimer's pathology), decreased beta-amyloid production, suppressed neuroinflammation via reduced NF-kB activation, and enhanced autophagy [2][7][8].

Lithium also modulates neurotransmitter systems (serotonin and norepinephrine), upregulates brain-derived neurotrophic factor (BDNF) expression, and promotes synaptogenesis through CREB phosphorylation — effects that occur independently of mood stabilization [2][7][9].

The question of whether lithium should be considered a "trace nutrient" remains debated. Americans typically consume approximately 0.6 to 3.1 mg of lithium daily from food and water, depending on geography and diet [10][11]. Some researchers have proposed that 1 mg per day represents an adequate intake to support brain health [11], though no formal dietary reference intake has been established by any major regulatory body. The wide variation in natural lithium exposure — from less than 0.001 mg/L to more than 1 mg/L in drinking water — has created natural experiments that epidemiologists have studied for associations with mental health outcomes [5][6][12].

Forms and Bioavailability

Lithium supplements are available in several chemical forms, each with different elemental lithium content, absorption characteristics, and safety profiles. Understanding these differences is essential for selecting an appropriate form and interpreting dosage information on supplement labels.

Form	Elemental Li (%)	Absorption	Primary Context	Key Notes
Lithium Orotate	3.83%	80–100% (estimated)	OTC supplement	Most common supplement form. Orotate moiety may facilitate brain uptake via urate transporters [2][13].
Lithium Aspartate	4.8%	Comparable to carbonate	OTC supplement	Used in some clinical studies. Aspartate is an excitatory amino acid [1][14].
Lithium Carbonate	18.8%	80–100% (well-established)	Prescription drug (bipolar)	Standard pharmaceutical form. Requires blood monitoring. High elemental Li per dose [3].
Lithium Citrate	~6% (varies)	Bioequivalent to carbonate	Prescription liquid; some OTC	Absorbed slightly faster than carbonate but same total bioavailability [15].
Lithium Chloride	16.4%	Good oral absorption	Historical (salt substitute)	Removed from market in 1949 due to toxicity at gram-level doses [16].

Lithium Orotate: The Dominant Supplement Form

Lithium orotate is the most widely sold low-dose lithium supplement form. It consists of lithium bound to orotic acid, a naturally occurring pyrimidine precursor [2][13]. The compound contains only 3.83% elemental lithium by weight — meaning a 130 mg lithium orotate tablet delivers approximately 5 mg of elemental lithium [2][13]. It typically appears as a white crystalline powder, odorless and tasteless, with sparing solubility in water.

The orotate form was first popularized in the 1970s by German physician Hans Nieper, who proposed that the orotate moiety acts as a carrier molecule, leveraging nucleotide salvage pathways and organic anion transporters (including urate transporter 1, hURAT1) to cross cell membranes and the blood-brain barrier more efficiently than inorganic lithium salts [2][7]. This hypothesis is supported by several lines of evidence:

Animal studies showing enhanced brain penetration: A foundational 1978 study found that when equal amounts of lithium were given to rats by injection, lithium orotate produced higher concentrations in serum and brain compared to lithium carbonate (Kling et al., J Pharm Pharmacol, 1978) [13]. More recent studies have confirmed approximately 2–3 times higher brain lithium concentrations from orotate versus carbonate at equivalent doses [2][7].

Greater potency in behavioral models: A 2022 preclinical investigation in a mouse model of amphetamine-induced mania found that lithium orotate was approximately 10-fold more potent than lithium carbonate — a minimal effective dose of 1.5 mg/kg lithium orotate achieved near-complete blockade of manic-like behaviors, compared to 15–20 mg/kg for lithium carbonate [7][17]. The behavioral effects of orotate lasted 12–36 hours versus shorter durations for carbonate [17].

Reduced toxicity at effective doses: In the same mouse mania model, lithium orotate at up to three times its minimal effective dose (4.5 mg/kg) produced no polydipsia (excessive thirst), no significant elevations in serum creatinine, blood urea nitrogen, or thyroid-stimulating hormone. In contrast, lithium carbonate induced polydipsia at doses of 30 mg/kg or higher and increased creatinine in males [17].

Lower affinity for amyloid plaques: A 2025 study published in Nature found that lithium orotate has reduced binding affinity to amyloid-beta plaques compared to lithium carbonate, allowing higher free lithium levels in brain tissue to inhibit GSK-3beta and reduce neuroinflammation — a critical advantage in the context of Alzheimer's disease [8].

However, significant caveats exist. A 1979 follow-up study found that the higher lithium accumulation from orotate could be explained by reduced kidney function — the orotate form caused kidney impairment in rats at the large doses used, leading to lithium retention rather than true enhanced delivery. The authors wrote: "It seems inadvisable to use lithium orotate for the treatment of patients" (Smith et al., J Pharm Pharmacol, 1979) [18]. This safety concern applies specifically to high doses; at the very low supplement doses (1–20 mg elemental lithium), such kidney toxicity has not been observed in over 40 years of commercial use [2][19].

Most pharmacokinetic data for lithium orotate derive from animal models, with limited human studies available. Peak plasma concentrations occur within 1–4 hours of oral administration. Lithium itself undergoes minimal metabolism and is excreted unchanged primarily via the kidneys (more than 95% of elimination), with a plasma half-life of approximately 24 hours [2][7]. A 2024 study using 7Li-MRI in 9 healthy adults demonstrated detectable lithium accumulation in the brain after 28 days of 5 mg daily lithium orotate supplementation, providing direct evidence that low-dose orotate achieves brain penetration in humans [20].

Lithium Aspartate

Lithium aspartate contains 4.8% elemental lithium and has been used in several clinical studies of low-dose lithium [1][14]. It has been tested at doses providing 0.383 to 1.7 mg of elemental lithium per day in long COVID trials [14]. Absorption and bioavailability appear comparable to lithium carbonate.

Lithium Citrate

Lithium citrate is available both as a prescription liquid and as a low-dose supplement. As a supplement, it typically provides 2 mg of lithium per dropper [1]. The citrate form is absorbed slightly faster than lithium carbonate tablets but is otherwise bioequivalent (Guelen et al., Biopharm Drug Dispos, 1992) [15]. Notably, lithium citrate is an FDA-approved drug form, raising regulatory questions about whether it can legally be sold as a dietary supplement [1].

Lithium Chloride: A Historical Cautionary Tale

Lithium chloride (16.4% lithium) was used in the late 1940s in the US as a liquid salt substitute. Side effects including weakness, drowsiness, and generalized tremors were reported in people consuming several grams daily (Hanlon et al., JAMA, 1949) [16], and the FDA ordered lithium salt substitutes removed from the market. Each gram of lithium chloride contains 164 mg of elemental lithium, and some people were consuming several times this amount daily.

How to Read a Supplement Label

Supplement labeling for lithium can be confusing because of the difference between the lithium compound weight and the elemental lithium content. This distinction matters enormously:

• Prescription lithium lists the dose as the compound weight: "900 mg lithium carbonate" contains 169 mg elemental lithium.
• Supplement lithium typically focuses on elemental lithium: "Lithium (as lithium orotate 131 mg) 5 mg" means the product contains 131 mg of the lithium orotate compound, delivering 5 mg of elemental lithium.
• Published research sometimes uses the term "lithium" when actually referring to a lithium compound, which can cause major confusion about effective doses.

Always compare products based on their elemental lithium content, not the weight of the lithium compound [1].

Mechanistic Comparisons Between Forms

In vitro studies reveal differences between lithium forms in enzyme inhibition. Lithium orotate selectively inhibits GSK-3beta at concentrations as low as 0.2 mM in hippocampal slices, enhancing long-term potentiation without disrupting synaptic plasticity. Inorganic lithium salts like lithium chloride require higher doses (0.6 mM or more) and exhibit inconsistent effects via non-GSK-3 pathways [7][21].

Lithium orotate also modulates the availability of serotonin and norepinephrine in the brain, potentially through increased release and enhanced sensitivity of postsynaptic 5-HT1A serotonin receptors and alpha-2 adrenergic receptors [2][7]. It exhibits anti-inflammatory effects in neural tissues by downregulating pro-inflammatory cytokines such as IL-6 and TNF-alpha through GSK-3 inhibition, reducing NF-kB activation in microglia and astrocytes [7]. Furthermore, it upregulates BDNF expression and fosters synaptogenesis via CREB phosphorylation, supporting neuronal survival and long-term brain resilience [2][7][9].

Evidence for Benefits

Mood, Suicide, and Mental Health

Lithium in Drinking Water and Suicide Risk

Some of the most intriguing evidence for low-dose lithium comes from ecological studies examining the relationship between naturally occurring lithium in drinking water and population-level mental health outcomes.

Early ecological studies: A pioneering 1990 study by Schrauzer and Shrestha analyzed lithium levels in drinking water across 27 Texas counties and found significant inverse correlations between water lithium concentrations and rates of suicide, homicide, and rape (Schrauzer et al., Biol Trace Elem Res, 1990) [22]. A subsequent Japanese study found similar inverse associations between water lithium levels and suicide rates (Sugawara et al., Int J Environ Res Pub Health, 2013) [23]. A 2024 meta-analysis of ecological studies estimated up to a 50% lower suicide risk in areas with higher natural lithium levels, suggesting a dose-independent anti-suicidal mechanism [24].

Critical counterevidence: However, a rigorous 2018 study from Parker and colleagues challenged these findings. After adjusting for healthcare resources and demographics by geography, the study found no association between lithium levels in groundwater and rates of mental illness. Regions with low lithium tended to be areas with far more medical resources, likely resulting in more diagnoses rather than more illness (Parker et al., JAMA Psychiatry, 2018) [25].

Danish dementia study: A large, long-term observational study in Denmark found an 18% lower risk of developing dementia in areas with higher lithium levels in drinking water (0.015 mg/L) compared to areas with the lowest levels (0.002–0.005 mg/L) (Kessing et al., JAMA Psychiatry, 2017) [6]. However, this does not prove cause-and-effect.

Synthesis: The ecological evidence linking trace lithium exposure to reduced suicide and violence rates is suggestive but not conclusive. The consistency of findings across multiple countries and the biological plausibility keep this hypothesis alive, but the strongest critique — that healthcare resource availability confounds the association — has not been adequately addressed [24][25].

Low-Dose Lithium for Depression and Mood

One psychiatrist has anecdotally reported benefits from prescribing 2 to 20 mg of lithium orotate daily to treat patients with aggression, depression, and other conditions (Greenblatt, Townsend Letter, 2015) [26]. This amount of lithium orotate would yield only 0.08 to 0.8 mg of elemental lithium.

A small study among former drug users given 0.4 mg of lithium daily from naturally lithium-rich brewer's yeast tablets suggested that this very low dose improved mood, including self-reported happiness (Schrauzer et al., Biol Trace Elem Res, 1994) [27].

A 2025 cross-sectional survey of 211 adults using over-the-counter lithium supplements (typically 5–10 mg elemental lithium daily) found that 19% reported improvements in mood and 20% in anxiety symptoms, with 31% identifying mood enhancement as their primary reason for taking lithium [28]. Moderate benefits were the most commonly reported level (58% of respondents). However, the study relied on self-reports with no placebo control [28].

Observational reports suggest 20–30% improvements on validated depression scales in small cohorts using adjunctive low-dose lithium (including orotate forms). Effect sizes for mood stabilization with low-dose lithium range from 0.4 to 0.6, lower than the 0.8 observed with therapeutic-dose lithium carbonate, but associated with improved tolerability [2][30].

Synthesis: Human evidence for low-dose lithium's effects on mood and depression is preliminary and largely observational or anecdotal. No well-powered, placebo-controlled RCTs specifically evaluate lithium orotate for depression. The biological plausibility is strong, but clinical proof for low-dose supplementation is lacking [1][2].

Alcoholism and Addiction

A 1986 open-label study by Sartori involving 42 alcoholic patients receiving 150 mg/day lithium orotate (approximately 5.7 mg elemental lithium) during rehabilitation demonstrated reduced alcohol cravings, with 23 patients showing no relapse over 1–10 years and concurrent alleviation of depressive symptoms [31]. Nieper's earlier observations in a two-year open-label study from 1973 reported mood stabilization in patients treated with 150–300 mg/day lithium orotate (5–12 mg elemental lithium) without the gastrointestinal side effects commonly associated with lithium carbonate [32].

These early studies were hampered by small sample sizes (n<50), absence of placebo controls, and open-label designs [2]. No randomized controlled trials have evaluated lithium orotate for addiction.

Cognitive Impairment, Alzheimer's Disease, and Dementia

Low-dose lithium has generated significant research interest for its potential neuroprotective effects in cognitive decline and neurodegenerative diseases. The evidence spans epidemiological associations, clinical trials at varying lithium doses, and compelling preclinical data.

Alzheimer's Disease

Low-dose clinical trial (positive): A 15-month, placebo-controlled study used just 0.3 mg per day of lithium (from a 1.5 mg dose of lithium carbonate) in patients with Alzheimer's disease. This very low dose stabilized cognitive impairment, with evidence of benefit compared to placebo beginning three months into treatment and increasing over time (Nunes et al., Curr Alzheimer Res, 2013) [33].

Higher-dose clinical trial (negative): An earlier 6-month study among 70 people (average age 69) with mild Alzheimer's disease evaluated lithium started at approximately 5.3 mg of elemental lithium (from 42 mg of lithium sulfate) and titrated until blood levels reached 0.5–0.8 mmol/L (maximum ~42 mg lithium from 336 mg lithium sulfate). This study found no significant improvement in overall cognitive function or Alzheimer's symptoms compared to placebo (Hampel et al., J Clin Psychiatry, 2009) [34]. Although lithium increased BDNF levels in a subset of participants, this was not linked with cognitive improvements (Leyhe et al., J Alzheimers Dis, 2009) [35].

Preclinical breakthrough (2025 Nature study): A landmark 2025 study published in Nature found that endogenous lithium levels are dynamically regulated in the brain and are significantly depleted in Alzheimer's disease. Postmortem analyses revealed reduced lithium in the prefrontal cortex of individuals with MCI and Alzheimer's compared to controls. Amyloid plaques sequester lithium ions, depleting available lithium in the brain and potentially explaining the failure of trials with lithium carbonate — the carbonate form binds strongly to plaques and becomes sequestered [8].

In mouse models of Alzheimer's disease (3xTg and J20 strains) and aged wild-type mice, ultra-low dose lithium orotate (approximately 1/1000th of typical therapeutic lithium carbonate equivalents, around 4.3 micromolar in drinking water) prevented and reversed key pathologies [8]:

• Approximately 70% reduction in amyloid-beta plaque burden
• Decreased phospho-tau accumulation
• Reduced neuroinflammation
• Preservation of synapses and myelin
• Restoration of memory function

Critically, these effects were not observed with lithium carbonate at equivalent doses due to the carbonate form's sequestration by amyloid plaques. The superior efficacy of orotate stems from its lower affinity for amyloid binding, enabling higher free lithium levels in brain tissue to inhibit GSK-3beta [8]. In vitro assays showed lithium orotate inhibits amyloid-beta aggregation more effectively than carbonate, with up to 30% plaque reduction without added toxicity [8].

Mild Cognitive Impairment

Positive trial (moderate-dose lithium): A small, placebo-controlled study in Brazil of elderly people with mild cognitive impairment found that lithium given daily for one year decreased P-tau levels and improved certain cognitive tests. The dose ranged from 150 to 600 mg of lithium carbonate (28 to 113 mg of elemental lithium) — higher than typical supplement doses (Forlenza et al., Br J Psych, 2011) [37]. An extended follow-up showed increased adverse effects (Aprahamian et al., J Clin Psych, 2014) [38].

Negative trial (lower-dose lithium): A study among 80 adults (average age 72) with mild cognitive impairment showed that 150 or 300 mg of lithium carbonate (approximately 28 to 56 mg of elemental lithium) daily for 2 years did not significantly slow the decline in overall cognitive function or visual memory compared to placebo (Gildengers et al., JAMA Neurol, 2026) [39].

Synthesis: The most encouraging result comes from the Nunes 2013 study using 0.3 mg/day — a true micro-dose that showed cognitive stabilization. The 2025 Nature preclinical data provide a compelling mechanistic explanation for why lithium orotate may be more effective than lithium carbonate in Alzheimer's disease. Clinical trials are being planned as of 2026 [8][20].

BDNF and Neuroprotection

Lithium's neuroprotective effects are mediated in part through upregulation of BDNF, a protein that promotes neuronal survival, dendritic arborization, and synaptic plasticity [2][9]. GSK-3 inhibition activates CREB phosphorylation, enhancing BDNF transcription and release [2][9]. BDNF depletion is a consistent finding in Alzheimer's disease, Parkinson's disease, depression, and age-related cognitive decline [2][9].

Traumatic Brain Injury

Preclinical data suggest that low-dose lithium orotate may aid recovery from traumatic brain injury by promoting neuronal survival and synaptogenesis. In TBI models, low-dose lithium mitigates oxidative damage and enhances cognitive rehabilitation through reduced apoptosis and increased synaptic plasticity [40]. Human data on lithium for TBI are absent.

Long COVID

A small study among 50 adults (average age 59) with fatigue and cognitive dysfunction related to long COVID showed that 10 to 15 mg of lithium aspartate (providing 0.383 to 0.575 mg of elemental lithium) daily for 3 weeks did not significantly improve fatigue or cognitive dysfunction compared to placebo [14].

A subsequent open-label follow-up study among just 5 people with long COVID found that a higher dose of lithium aspartate (40 to 45 mg/day, providing approximately 1.5 to 1.7 mg/day of elemental lithium) did improve cognitive dysfunction and fatigue in those who achieved blood levels of 0.18 to 0.50 mEq/L (Guttuso Jr. et al., JAMA Netw Open, 2024) [14]. Larger, controlled studies are needed [14].

Longevity and Anti-Aging

Lithium's anti-aging potential is rooted in several molecular mechanisms that intersect with known aging pathways [2][7]:

• Autophagy enhancement: GSK-3 inhibition promotes autophagy — the cellular cleanup process that degrades damaged proteins and organelles. Impaired autophagy is a hallmark of aging [2][7].
• Anti-inflammatory effects: Lithium downregulates pro-inflammatory cytokines including IL-6 and TNF-alpha, attenuating chronic low-grade inflammation (inflammaging) [7].
• Oxidative stress reduction: Lithium lowers reactive oxygen species and cytokine production in neurons [2][30].
• Cellular senescence: GSK-3 inhibition may reduce cellular senescence, limiting the secretion of inflammatory molecules that damage surrounding tissue [30].

Epidemiological data associating trace lithium intake with lower rates of dementia, suicide, and mortality provide indirect evidence for a longevity benefit, though confounders make causal claims premature [5][6][24].

Migraine Prophylaxis

Noncontrolled studies indicate that low doses of lithium may alleviate migraine frequency and severity by modulating serotonin pathways and reducing neurogenic inflammation [41]. Hans Nieper filed a patent in 1974 for lithium orotate's application in treating migraines. However, rigorous controlled trial data are lacking. Typical reported dosages range from 1–5 mg elemental lithium daily [29][41].

Recommended Dosing

No Established Effective Dose

Meaningful clinical studies with low-dose lithium supplements remain limited, making it impossible to determine a well-validated "effective dose" for any specific indication [1]. The following dosing guidance reflects what has been used in research and clinical practice, not proven therapeutic thresholds.

Context	Elemental Li Dose	Form Used	Source
General brain health / trace supplementation	0.5–1 mg/day	Orotate or aspartate	Schrauzer (2002) [11]
Mood support (general)	0.4 mg/day	Lithium-rich brewer's yeast	Schrauzer (1994) [27]
Mood support (psychiatric adjunct)	5–20 mg/day	Orotate	Greenblatt (2015) [26]
Alzheimer's stabilization (micro-dose)	0.3 mg/day	Carbonate	Nunes (2013) [33]
Cognitive impairment (moderate dose)	28–113 mg/day	Carbonate (prescription)	Forlenza (2011) [37]
Long COVID (exploratory)	0.4–1.7 mg/day	Aspartate	Guttuso (2024) [14]
Alcoholism (historical)	5–6 mg/day	Orotate (150 mg compound)	Sartori (1986) [31]

Practical Dosing Considerations

Starting dose: For general supplementation, 1 mg of elemental lithium per day is the most conservative dose, roughly equal to what the average American gets from food and water combined [1][11].

Common supplement doses: Most commercially available lithium orotate products provide 5 mg of elemental lithium per capsule (from approximately 130 mg of lithium orotate). Some products provide lower doses of 0.5–1 mg [1]. If a lower dose is desired, it is possible to open a 5 mg capsule and take a portion of the contents [1].

Elemental lithium vs. compound weight: Always check the label for elemental lithium content. A "120 mg lithium orotate" capsule contains approximately 4.6 mg elemental lithium, while a "5 mg lithium" capsule contains 5 mg elemental lithium from approximately 131 mg lithium orotate [1][2].

Hydration: Because lithium is excreted primarily through the kidneys, adequate hydration is important even at low doses. Dehydration increases the concentration of lithium in the body (Gitlin, Int J Bipolar, 2016) [43].

Safety and Side Effects

At Very Low Supplement Doses (1–5 mg Elemental Lithium)

At the doses found in most over-the-counter supplements (1–5 mg of elemental lithium per day), no significant adverse effects have been reported in clinical observations or in over 40 years of commercial supplement use in North America [2][7][19]. These doses do not produce serum lithium levels anywhere near the therapeutic/toxic range. Serum lithium levels below 0.5 mM are generally considered safe without the renal or thyroid risks seen at higher therapeutic doses [30].

One case report of overdose involving ingestion of 18 tablets (approximately 69 mg elemental lithium) resulted in only mild symptoms including nausea and tremors, which resolved spontaneously within three hours [19].

At Low-to-Moderate Supplement Doses (5–20 mg Elemental Lithium)

At doses of 5–20 mg elemental lithium per day, lithium orotate is associated with minimal adverse effects in most users [7]. At the upper end (above 20 mg/day), possible effects include mild gastrointestinal upset (nausea, diarrhea) in approximately 10–20% of users, tremor, fatigue, increased thirst, excessive urination, and weight gain — all dose-dependent and typically reversible [44][45].

At Moderate Doses (28–56 mg Elemental Lithium)

A clinical study by Gildengers et al. (2026) found that adults given 150 or 300 mg of lithium carbonate (providing 28 to 56 mg of elemental lithium) daily for two years reported substantially higher rates of side effects than placebo [39]:

Side Effect	Lithium Group	Placebo Group
Diarrhea	29%	15%
Tiredness	29%	15%
Tremor	24%	15%
Increased TSH (thyroid)	17%	8%
Weight gain	17%	10%
Headache	12%	5%
Increased blood calcium	12%	0%
Leg swelling	12%	3%
Nausea	10%	5%
Stomach discomfort	10%	3%

At Higher Doses (28–113 mg Elemental Lithium)

A 4-year extended follow-up study involving 150 to 600 mg of lithium carbonate (providing 28 to 113 mg of elemental lithium) given to elderly people in Brazil found no kidney function impairment. However, those receiving lithium were significantly more likely to develop diabetes (20%), arrhythmia (20%), weight gain (25%, averaging 12 lbs), and increased TSH levels during the first two years [38].

Thyroid Effects

Long-term exposure to high or even moderate amounts of lithium can affect thyroid function, causing hypothyroidism. This was demonstrated in a study in the Argentine Andes where daily lithium intake from drinking water may have been as high as 30 mg per day (Broberg et al., Environ Health Perspect, 2011) [46]. Whether truly low doses (1–5 mg/day) affect thyroid function is unknown; the risk appears primarily a concern at moderate-to-high doses [2][7].

Kidney Effects

Long-term use of lithium at pharmacological doses (169–338 mg elemental lithium per day) has been clearly associated with kidney disease [3][4]. At lower doses, kidney toxicity has not been demonstrated in humans. The Aprahamian 4-year study using 28–113 mg/day found no kidney impairment [38]. At very low supplement doses (1–5 mg/day), no kidney effects have been reported [2][19].

General Toxicity

Most lithium toxicity is mild: lethargy, vomiting, difficulty with balance, and muscle tremors [1]. Larger doses or chronic high-dose use can cause coma or seizures (Pauze et al., J Med Toxicol, 2007) [47]. Serum lithium above 1.5 mEq/L carries risks of confusion, ataxia, and gastrointestinal distress — levels not achievable with typical low-dose supplements [2][3].

Risk Factors for Lithium Accumulation

• Dehydration — impairs renal excretion
• Low-sodium diets — enhance tubular reabsorption of lithium
• Renal impairment — reduced lithium clearance
• Elderly age — age-related declines in kidney function (50% dose reduction often recommended) [45]
• Dietary sodium variability — sudden changes can alter lithium levels

Contraindications

• Severe renal impairment (GFR below 30 mL/min) — risk of lithium accumulation and toxicity
• Untreated hypothyroidism — lithium can exacerbate thyroid dysfunction
• Pregnancy — teratogenic risk, particularly for cardiac malformations (Ebstein's anomaly) in the first trimester
• Cardiac arrhythmias — lithium can affect cardiac conduction
• Children — limited safety data [2][7][45][48]

Drug Interactions

Drug interactions with lithium orotate mirror those of other lithium formulations, primarily involving agents that alter renal clearance or enhance lithium retention [2][49][50][51].

Drugs That Increase Lithium Levels

Drug Class	Examples	Mechanism	Risk Magnitude
Thiazide diuretics	Hydrochlorothiazide	Enhanced proximal tubular reabsorption	~25% increase in serum Li [49]
NSAIDs	Ibuprofen, naproxen, celecoxib	Reduced lithium clearance	20–40% increase [50]
ACE inhibitors	Lisinopril, enalapril	Decreased glomerular filtration rate	Variable [51]
ARBs	Losartan, valsartan	Similar to ACE inhibitors	Variable [51]

Other Notable Interactions

• SSRIs and serotonergic drugs: Combining lithium with SSRIs may increase the risk of serotonin syndrome, primarily documented at pharmacological doses [2][29].
• Alcohol: Not recommended. Alcohol can potentiate CNS side effects and, as a diuretic, promotes dehydration which impairs renal lithium excretion [2].
• Dietary sodium: Variability should be minimized. Sudden sodium increases lower lithium levels; sodium restriction raises them [52].
• Prescription lithium: Never combine OTC lithium supplements with prescription lithium without physician supervision — additive toxicity risk [2].

While these interactions are documented primarily at pharmacological lithium doses, they are worth being aware of at lower supplement doses, especially in elderly individuals, those on multiple medications, or those with any degree of renal impairment [1][2].

Dietary Sources

Lithium in Drinking Water

Lithium concentrations in drinking water vary by orders of magnitude worldwide [5][6][10]:

• Very low: 0.001–0.005 mg/L (typical of many European regions, including Denmark)
• Low-to-moderate: 0.005–0.050 mg/L (typical of many US water supplies)
• Moderate-to-high: 0.050–0.170 mg/L (some US regions, parts of South America)
• High: Up to 1 mg/L or more (parts of the Argentine Andes, some regions of Chile)

The US Geological Survey has mapped lithium levels in groundwater across the United States, showing wide geographical variation [53]. An individual drinking 2 liters per day from a water supply with 0.01 mg/L lithium would receive 0.02 mg (20 micrograms) daily from water alone.

Lithium in Food

Lithium is present in most foods at trace levels. The richest dietary sources include [10][11]:

• Grains and cereals — lithium accumulates in cereal crops from soil
• Vegetables — particularly nightshade family (tomatoes, potatoes, peppers)
• Legumes and pulses
• Dairy products
• Eggs
• Meat and fish — generally lower concentrations

The total dietary lithium intake for Americans is estimated at approximately 0.6 to 3.1 mg per day, depending on diet composition and geographic origin of foods [10][11].

Lithium-Rich Brewer's Yeast

Some specialty products contain naturally lithium-enriched brewer's yeast, which has been used in research. The Schrauzer 1994 mood study used lithium-rich brewer's yeast tablets providing 0.4 mg of lithium per day [27].

No Established Dietary Reference Intakes

Unlike essential minerals with established recommended intakes, lithium has no RDA, AI (Adequate Intake), or UL (Tolerable Upper Intake Level) set by any major regulatory body. The 1 mg/day suggestion by Schrauzer (2002) remains a researcher's recommendation, not an official guideline [11]. The enormous geographic variation in natural lithium exposure makes it difficult to establish "normal" or "optimal" intake.

Regulatory Status

In the United States, lithium orotate is classified as a dietary supplement under DSHEA (1994) and does not require pre-market FDA approval [2]. In the EU, it has novel food status requiring pre-market authorization (not yet granted as of late 2025). In Canada, it is classified as a prescription drug. In Australia, it is a listed complementary medicine at low doses (typically under 5 mg elemental lithium) [2].

References

1. ConsumerLab. "Lithium Supplements Review." Accessed 2025. https://www.consumerlab.com/reviews/lithium-low-dose-supplements/lithium/

2. Grokipedia. "Lithium orotate." Accessed 2025. https://grokipedia.com/page/Lithium_orotate

3. Lithium Prescribing Information. 2018. U.S. Food and Drug Administration.

4. Gitlin M. "Lithium side effects and toxicity: prevalence and management strategies." Int J Bipolar Disord. 2016;4(1):27. https://doi.org/10.1186/s40345-016-0068-y

5. Kessing LV, Gerds TA, Knudsen NN, et al. "Association of Lithium in Drinking Water With the Incidence of Dementia." JAMA Psychiatry. 2017;74(10):1005-1010. https://doi.org/10.1001/jamapsychiatry.2017.2362

6. Kessing LV, Gerds TA, Knudsen NN, et al. "Lithium in Drinking Water and Dementia Risk (Denmark)." JAMA Psychiatry. 2017;74(10):1005-1010. https://doi.org/10.1001/jamapsychiatry.2017.2362

7. Grokipedia. "Lithium orotate — Pharmacology." Accessed 2025. https://grokipedia.com/page/Lithium_orotate

8. Bhatt V, et al. "Lithium deficiency in Alzheimer's disease and lithium orotate as neuroprotective agent." Nature. 2025.

9. Hashimoto R, Takei N, Shimazu K, et al. "Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons." Neuropharmacology. 2002;43(7):1173-1179. https://doi.org/10.1016/S0028-3908(02)00217-4

10. Schrauzer GN. "Lithium: occurrence, dietary intakes, nutritional essentiality." J Am Coll Nutr. 2002;21(1):14-21. https://doi.org/10.1080/07315724.2002.10719188

11. Schrauzer GN. "Lithium: occurrence, dietary intakes, nutritional essentiality." J Am Coll Nutr. 2002;21(1):14-21. https://doi.org/10.1080/07315724.2002.10719188

12. US Geological Survey. "Lithium in Groundwater Used for Drinking-Water Supply in the United States." Scientific Investigations Report 2013/5170. https://pubs.usgs.gov/sir/2013/5170/

13. Kling MA, Manowitz P, Pollack IW. "Rat brain and serum lithium concentrations after acute injections of lithium carbonate and orotate." J Pharm Pharmacol. 1978;30(6):368-370. https://doi.org/10.1111/j.2042-7158.1978.tb13259.x

14. Guttuso T Jr., Zhu R, Wilding GE. "Low-Dose Lithium for Long COVID." JAMA Netw Open. 2024;7(10):e2440326. https://doi.org/10.1001/jamanetworkopen.2024.40326

15. Guelen PJM, et al. "Bioavailability of lithium from lithium citrate syrup versus conventional lithium carbonate tablets." Biopharm Drug Dispos. 1992;13(3):225-230. https://doi.org/10.1002/bdd.2510130308

16. Hanlon LW, et al. "Lithium chloride as a substitute for sodium chloride in the diet." JAMA. 1949;139(11):688-692. https://doi.org/10.1001/jama.1949.02900280012004

17. 2022 mouse mania model study: lithium orotate vs lithium carbonate potency comparison. Referenced via Grokipedia. https://grokipedia.com/page/Lithium_orotate

18. Smith DF, Schou M. "Kidney function and lithium concentrations of rats given an injection of lithium orotate or lithium carbonate." J Pharm Pharmacol. 1979;31(3):161-163. https://doi.org/10.1111/j.2042-7158.1979.tb13465.x

19. Grokipedia. "Lithium orotate — Safety profile." https://grokipedia.com/page/Lithium_orotate

20. 2024 7Li-MRI study in 9 healthy adults: brain lithium accumulation after 28 days of 5 mg daily lithium orotate. Referenced via Grokipedia.

21. Grokipedia. In vitro GSK-3beta inhibition comparison: lithium orotate vs lithium chloride. https://grokipedia.com/page/Lithium_orotate

22. Schrauzer GN, Shrestha KP. "Lithium in drinking water and the incidences of crimes, suicides, and arrests related to drug addictions." Biol Trace Elem Res. 1990;25(2):105-113. https://doi.org/10.1007/BF02990271

23. Sugawara N, et al. "Lithium in tap water and suicide mortality in Japan." Int J Environ Res Public Health. 2013;10(11):6044-6048. https://doi.org/10.3390/ijerph10116044

24. 2024 meta-analysis of ecological studies: trace lithium in drinking water and suicide rates. Referenced via Grokipedia.

25. Parker WF, et al. "Association Between Groundwater Lithium and the Diagnosis of Bipolar Disorder and Dementia in the United States." JAMA Psychiatry. 2018;75(5):458-465. https://doi.org/10.1001/jamapsychiatry.2018.0163

26. Greenblatt JM. "Low-Dose Lithium for Mental Health." Townsend Letter. 2015.

27. Schrauzer GN, de Vroey E. "Effects of nutritional lithium supplementation on mood." Biol Trace Elem Res. 1994;40(1):89-101. https://doi.org/10.1007/BF02916824

28. 2025 cross-sectional survey of 211 adults using OTC lithium supplements. Referenced via Grokipedia.

29. Grokipedia. "Lithium orotate — Psychiatric applications." https://grokipedia.com/page/Lithium_orotate

30. Grokipedia. "Lithium orotate — Broader neuroprotective directions and anti-aging mechanisms." https://grokipedia.com/page/Lithium_orotate

31. Sartori HE. "Lithium orotate in the treatment of alcoholism and related conditions." Alcohol. 1986;3(2):97-100. https://doi.org/10.1016/0741-8329(86)90018-2

32. Nieper HA. "The clinical applications of lithium orotate." Agressologie. 1973;14(6):407-411.

33. Nunes MA, Viel TA, Buck HS. "Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease." Curr Alzheimer Res. 2013;10(1):104-107. https://doi.org/10.2174/1567205011310010014

34. Hampel H, et al. "Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study." J Clin Psychiatry. 2009;70(6):922-931. https://doi.org/10.4088/JCP.08m04606

35. Leyhe T, et al. "Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease." J Alzheimers Dis. 2009;16(3):649-656. https://doi.org/10.3233/JAD-2009-1004

36. Grokipedia. "Lithium orotate — Alzheimer's disease investigations: 2025 epidemiological data." https://grokipedia.com/page/Lithium_orotate

37. Forlenza OV, et al. "Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment." Br J Psychiatry. 2011;198(5):351-356. https://doi.org/10.1192/bjp.bp.110.080044

38. Aprahamian I, et al. "Long-term, low-dose lithium treatment does not impair renal function in the elderly." J Clin Psychiatry. 2014;75(7):e672-e678. https://doi.org/10.4088/JCP.13m08741

39. Gildengers AG, et al. "Effect of Lithium vs Placebo on Cognitive Decline in Early Mild Cognitive Impairment." JAMA Neurol. 2026. https://doi.org/10.1001/jamaneurol.2025.4759

40. Grokipedia. "Lithium orotate — TBI neuroprotection." https://grokipedia.com/page/Lithium_orotate

41. Grokipedia. "Lithium orotate — Migraine prophylaxis." https://grokipedia.com/page/Lithium_orotate

42. Life Extension. "Lithium brain health supplement: 1 mg elemental lithium per capsule from lithium orotate." Referenced via Grokipedia.

43. Gitlin M. "Lithium side effects and toxicity." Int J Bipolar Disord. 2016;4(1):27. https://doi.org/10.1186/s40345-016-0068-y

44. Grokipedia. "Lithium orotate — Adverse effects." https://grokipedia.com/page/Lithium_orotate

45. Grokipedia. "Lithium orotate — Safety profile: contraindications and special populations." https://grokipedia.com/page/Lithium_orotate

46. Broberg K, et al. "Lithium in drinking water and thyroid function." Environ Health Perspect. 2011;119(6):827-830. https://doi.org/10.1289/ehp.1002678

47. Pauze DK, Brooks DE. "Lithium toxicity from an internet dietary supplement." J Med Toxicol. 2007;3(2):61-62. https://doi.org/10.1007/BF03160909

48. Grokipedia. "Lithium orotate — Teratogenic risk." https://grokipedia.com/page/Lithium_orotate

49. Grokipedia. "Lithium orotate — Drug interactions: thiazide diuretics." https://grokipedia.com/page/Lithium_orotate

50. Grokipedia. "Lithium orotate — Drug interactions: NSAIDs." https://grokipedia.com/page/Lithium_orotate

51. Grokipedia. "Lithium orotate — Drug interactions: ACE inhibitors." https://grokipedia.com/page/Lithium_orotate

52. Grokipedia. "Lithium orotate — Dietary sodium variability." https://grokipedia.com/page/Lithium_orotate

53. US Geological Survey. "Lithium in Groundwater Used for Drinking-Water Supply in the United States." Scientific Investigations Report 2013/5170. https://pubs.usgs.gov/sir/2013/5170/